keyword
MENU ▼
Read by QxMD icon Read
search

Vinorelbine

keyword
https://www.readbyqxmd.com/read/29928211/small-cell-carcinoma-transformation-of-pulmonary-adenocarcinoma-after-osimertinib-treatment-a-case-report
#1
Yuri Taniguchi, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui
There are various mechanisms underlying the resistance of EGFR-mutant lung adenocarcinoma to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We herein report a case of pulmonary adenocarcinoma with EGFR mutation (exon 19 deletion and T790M) that acquired resistance to osimertinib treatment because of transformation into small-cell lung carcinoma (SCLC). A 67-year-old ex-smoking woman was diagnosed with left upper lobe adenocarcinoma of clinical stage IIIA (cT2bN2M0). She was treated with chemoradiotherapy (cisplatin and vinorelbine plus radiation), gefitinib, cisplatin, and pemetrexed followed by pemetrexed maintenance therapy and erlotinib...
May 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/29917332/comparing-first-line-treatment-patterns-and-clinical-outcomes-of-patients-with-pan-negative-advanced-non-squamous-non-small-cell-lung-cancer
#2
Haiyan Xu, Fei Xu, Wenjie Zhu, Jianming Ying, Yan Wang
BACKGROUND: Platinum-based chemotherapy is the standard first-line treatment for patients with advanced pan-negative non-squamous (non-Sq) non-small cell lung cancer (NSCLC). However, it is unknown which chemotherapy regimen confers the greatest benefit in such patients. This study explored which chemotherapy regimens were advantageous in non-Sq NSCLC patients. METHODS: A retrospective study was conducted on 114 patients with advanced non-Sq NSCLC using platinum-based chemotherapy in a first-line setting between January 2013 and December 2015...
June 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29912578/real-life-adjuvant-chemotherapy-uptake-and-survival-in-patients-with-non-small-cell-lung-cancer-after-complete-resection
#3
Vítězslav Kolek, Stanislav Losse, Juraj Kultan, Petr Jakubec, Jaromir Zatloukal, Milan Sova, Marek Szkorupa, Čestmír Neoral, Josef Škarda, Tomáš Tichý, Zdeněk Kolář
OBJECTIVES: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies with non-conclusive results. MATERIAL AND METHODS: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stage IB (tumor of ≥4 cm in diameter), II and IIIA and reasons of AC omission were evaluated according to medical records...
June 18, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29902087/treatment-of-advanced-breast-cancer-with-a-metronomic-schedule-of-oral-vinorelbine-what-is-the-opinion-of-italian-oncologists
#4
Marina E Cazzaniga, Elisabetta Munzone, Emilia Montagna, Giovanni Pappagallo
BACKGROUND: The aim of this study was to record the opinions of Italian oncologists about the use of oral vinorelbine administered metronomically in patients with advanced breast cancer. METHODS: A series of meetings were held throughout Italy and participants were asked how much they agreed with each of several statements. RESULTS: The majority of oncologists agreed that the concept of the minimum biologically effective dose should be used for drugs administered metronomically...
June 14, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29861395/a-randomized-phase-iii-study-comparing-carboplatin-with-nab-paclitaxel-versus-docetaxel-for-elderly-patients-with-squamous-cell-lung-cancer-study-protocol
#5
Yoshihito Kogure, Hideo Saka, Yuichi Takiguchi, Shinji Atagi, Takayasu Kurata, Noriyuki Ebi, Akira Inoue, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Akiko Kada, Takeharu Yamanaka, Masahiko Ando, Nobuyuki Yamamoto, Akihiko Gemma, Yukito Ichinose
BACKGROUND: Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older...
May 19, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29858022/impact-of-a-comprehensive-geriatric-assessment-to-manage-elderly-patients-with-locally-advanced-non-small-cell-lung-cancers-an-open-phase-ii-study-using-concurrent-cisplatin-oral-vinorelbine-and-radiotherapy-gfpc-08-06
#6
Chrystèle Locher, Nicolas Pourel, Hervé Le Caer, Henri Berard, Jean-Bernard Auliac, Isabelle Monnet, Renaud Descourt, Alain Vergnenègre, Isabelle Martel Lafay, Laurent Greillier, Christos Chouaïd
INTRODUCTION: Few data have been published on the optimal management of elderly patients with locally advanced non-small-cell lung cancers (La-NSCLC). This prospective, multicenter, phase II study was undertaken to evaluate the ability of a comprehensive geriatric assessment (CGA) to select the elderly La-NSCLC patients who potentially may benefit from concurrent radio-chemotherapy. METHODS: The main inclusion criteria were: La-NSCLC, >70 years old, at least one measurable target, ECOG performance status (PS) 0/1 and normal CGA...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29848729/oral-metronomic-vinorelbine-in-advanced-non-small-cell-lung-cancer-patients-unfit-for-chemotherapy
#7
Giuseppe L Banna, Andrea Camerini, Giuseppe Bronte, Giuseppe Anile, Alfredo Addeo, Francesco Rundo, Guido Zanghì, Rohit Lal, Massimo Libra
AIM: To explore the feasibility and activity of oral metronomic vinorelbine patients with advanced NSCLC not eligible to standard chemotherapy because of old age (≥70 years), and/or poor Eastern Cooperative Oncology Group performance status (≥2), and/or extensive brain or bone disease, and/or active comorbidities (≥2) requiring for pharmacological treatment. PATIENTS AND METHODS: In a prospective phase II not randomized study, patients with stage IV NSCLC unfit to chemotherapy were treated with oral metronomic vinorelbine at 30 mg fixed dose three times a week until disease progression...
June 2018: Anticancer Research
https://www.readbyqxmd.com/read/29807624/high-throughput-scaffold-based-3d-micro-tumor-array-for-efficient-drug-screening-and-chemosensitivity-testing
#8
Xiaojun Yan, Lyu Zhou, Zhaozhao Wu, Xun Wang, Xiuyuan Chen, Fan Yang, Yanan Guo, Min Wu, Yuyang Chen, Wenjing Li, Jun Wang, Yanan Du
Oncology drug development is greatly hampered by inefficient drug screening using 2D culture. Herein, we present ready-to-use micro-scaffolds in 384-well format to generate uniform 3D micro-tumor array (3D-MTA, CV < 0.15) that predicts in vivo drug responses more accurately than 2D monolayer. 3D-MTA generated from both cell lines and primary cells achieved high screen quality (Z' > 0.5), and were compatible with standard high throughput and high content instruments. Doxorubicin identified by 3D-MTA and 2D successfully inhibited tumor growth in mice bearing lung cancer cell line (H226) xenografts, but not gemcitabine and vinorelbine, which were selected solely by 2D...
May 16, 2018: Biomaterials
https://www.readbyqxmd.com/read/29785284/vinorelbine-induced-regression-of-a-choroidal-metastasis-from-primary-breast-carcinoma
#9
Malvika Arya, Jay S Duker
Background: Various therapeutic options exist to treat choroidal metastatic lesions. However, they are all associated with potential long-term adverse effects. This case report discusses a case of choroidal metastasis from primary breast carcinoma that regressed after single-agent chemotherapy. Case presentation: We report a case of choroidal metastasis from estrogen receptor (ER) positive breast carcinoma that became resistant to endocrine therapy. The primary malignancy was treated with surgical resection and adjuvant chemoradiation, followed by hormone therapy with various agents in combination with kinase inhibitors for ER resistance...
2018: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/29767306/correction-to-results-of-nimotuzumab-and-vinorelbine-radiation-and-re-irradiation-for-diffuse-pontine-glioma-in-childhood
#10
Maura Massimino, Veronica Biassoni, Rosalba Miceli, Elisabetta Schiavello, Monika Warmuth-Metz, Piergiorgio Modena, Michela Casanova, Emilia Pecori, Felice Giangaspero, Manila Antonelli, Francesca Romana Buttarelli, Paolo Potepan, Bianca Pollo, Raffaele Nunziata, Filippo Spreafico, Marta Podda, Andrea Anichini, Carlo Alfredo Clerici, Iacopo Sardi, Loris De Cecco, Udo Bode, Ferdinand Bach, Lorenza Gandola
The therapeutic experience reported in the paper was conceived after the use of nimotuzumab and radiotherapy (BSCPED-05 international multicentric trial, EUDRACT 2005-003100-11) in 2009 when we decided to explore the activity of the same combination plus vinorelbine (see the paper for the rationale).
May 16, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29753703/ngr-htnf-in-combination-with-best-investigator-choice-in-previously-treated-malignant-pleural-mesothelioma-ngr015-a-randomised-double-blind-placebo-controlled-phase-3-trial
#11
Vanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, Francesco Grossi, Jacek Jassem, Andreas Polychronis, Paolo Bidoli, Marcello Tiseo, Riyaz Shah, Paul Taylor, Silvia Novello, Alberto Muzio, Alessandra Bearz, Laurent Greillier, Floriana Fontana, Giulia Salini, Antonio Lambiase, Mary O'Brien
BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of first-line chemotherapy. NGR-hTNF is a vascular-targeting drug that increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment. In this trial, we aimed to investigate the efficacy and safety of NGR-hTNF in patients with malignant pleural mesothelioma who had progressed during or after a first-line treatment...
May 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29749011/rapid-lc-ms-ms-method-for-quantification-of-vinorelbine-and-4-o-deacetylvinorelbine-in-human-whole-blood-suitable-to-monitoring-oral-metronomic-anticancer-therapy
#12
Giuseppe Corona, Milena Gusella, Anna Gaspardo, Gianmaria Miolo, Laura Bertolaso, Elisa Pezzolo, Felice Pasini, Agostino Steffan, Donatella Caruso
A rapid and sensitive LC-MS/MS method for therapeutic drug monitoring oral vinorelbine (VRL) metronomic anticancer chemotherapy has been developed and validated. Analysis of VRL and its main active metabolite 4-O-deacetylvinorelbine (M1) was performed in whole blood matrix. Both analytes were extracted by protein precipitation and separated on an Onyx monolith C18, 50 x 2 mm column then quantified by positive electrospray ionization and multiple reaction monitoring mode. The LLOQ was 0.05 ng/mL for both VRL and M1...
May 10, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29726786/surface-contamination-with-ten-antineoplastic-drugs-in-83-canadian-centers
#13
L Chauchat, C Tanguay, N J Caron, S Gagné, F Labrèche, J F Bussières
Purpose The aim of this study was to monitor environmental contamination by 10 antineoplastic drugs in Canadian oncology pharmacy and patient care areas. The secondary objective was to explore the impact of factors that may explain contamination. Methods Twelve standardized sites were sampled in each center (six in the pharmacy and six in patient care areas). Each sample was prepared to allow quantification of seven antineoplastic drugs (cyclophosphamide, ifosfamide, methotrexate, cytarabine, gemcitabine, 5-fluorouracil, irinotecan) by UPLC-MS-MS...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29714145/biological-activity-of-the-novel-vinca-alkaloids-4-chlorochablastine-and-4-chlorochacristine
#14
Gracia Montag, Helga Stopper, Quoc Anh Ngo, Henning Hintzsche
Vinca alkaloids are important cancer drugs belonging to the class of antimitotic agents. The most commonly used substances are vinblastine and vincristine, other compounds are vinorelbine and vinflunine. All of them are very effective drugs but their use is limited by severe side-effects including neurotoxicity and bone marrow depression. Therefore, it is very important to develop novel vinca alkaloids with similar efficacy but lower toxicity. Here, we analyzed two new compounds, 4-chlorochablastine and 4-chlorochacristine, with regard to their biological activity...
April 30, 2018: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/29705566/vinorelbine-cyclophosphamide-compared-to-cyclophosphamide-in-peripheral-blood-stem-cell-mobilization-for-multiple-myeloma
#15
Sanjay de Mel, Yunxin Chen, Adeline Lin, Teck Guan Soh, Melissa Ooi, Eng Soo Yap, Lara Kristina Sioco Donato, Nurul Aidah Abdul Halim, Joanna Mah, Karen Lim, Li Mei Poon, Belinda Tan, Yelly, Hui Li Lim, Liang Piu Koh, Bee Choo Tai, Zhaojin Chen, Wee Joo Chng, Satish Kumar Gopalakrishnan, Lip Kun Tan
BACKGROUND: High dose Cyclophosphamide (Cy) and Vinorelbine Cyclophosphamide (Vino-Cy) are stem cell (SC) mobilisation options for patients with multiple myeloma (MM). We present a comparison of mobilisation outcomes using these regimens. PATIENTS AND METHODS: Vino-Cy patients received Vinorelbine 25 mg/m2 on day 1, cyclophosphamide 1500 mg/m2 on day 2, and pegylated GCSF on day 4 or GCSF 10 mcg/kg/day from day 4 onwards. Cy patients were given cyclophosphamide 4000 mg/m2 on day 1 and GCSF10 mcg/kg/day from day 5 onwards...
April 23, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29696478/concurrent-chemoradiation-for-locally-advanced-stage-iii-non-small-cell-lung-cancer-with-cisplatin-vinorelbine-and-thoracic-radiotherapy-a-phase-ii-study-from-the-galician-lung-cancer-group
#16
M Costa Rivas, G Huidobro Vence, J L Fírvida Pérez, B Campos Balea, J García Gonzalez, M Lázaro Quintela, M Caeiro Muñoz, B Taboada Valladares, J E Castro Gómez, S Vázquez Estevez, F J Afonso Afonso, C Azpitarte Raposeiras, M Amenedo Gancedo, J Casal Rubio
PURPOSE: The aim of this phase II study was to evaluate the activity and safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy in unresectable locally advanced stage III non-small cell lung cancer (NSCLC). The primary endpoint was the objective response rate (ORR). Secondary objectives included toxicity profile, progression-free survival (PFS), and overall survival (OS). MATERIALS AND METHODS: A total of 48 NSCLC patients were enrolled (median age 60 years, 52% stage IIIA and 48% stage IIIB, 52% adenocarcinoma)...
April 25, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29695766/vinorelbine-cyclophosphamide-and-5-fu-effects-on-the-circulating-and-intratumoural-landscape-of-immune-cells-improve-anti-pd-l1-efficacy-in-preclinical-models-of-breast-cancer-and-lymphoma
#17
Stefania Orecchioni, Giovanna Talarico, Valentina Labanca, Angelica Calleri, Patrizia Mancuso, Francesco Bertolini
BACKGROUND: Anti-PD-1 and anti-PD-L1 checkpoint inhibitors (CIs) are clinically active in many types of cancer. However, only a minority of patients achieve a complete and/or long-lasting clinical response. We studied the effects of different doses of three widely used, orally active chemotherapeutics (vinorelbine, cyclophosphamide and 5-FU) over local and metastatic tumour growth, and the landscape of circulating and tumour-infiltrating immune cells involved in CI activity. METHODS: Immunocompetent Balb/c mice were used to generate models of breast cancer (BC) and B-cell lymphoma...
May 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29689640/haploid-genetic-screens-identify-genetic-vulnerabilities-to-microtubule-targeting-agents
#18
Nora M Gerhards, Vincent A Blomen, Merve Mutlu, Joppe Nieuwenhuis, Denise Howald, Charlotte Guyader, Jos Jonkers, Thijn R Brummelkamp, Sven Rottenberg
The absence of biomarkers to accurately predict anticancer therapy response remains a major obstacle in clinical oncology. We applied a genome-wide loss-of-function screening approach in human haploid cells to characterize genetic vulnerabilities to classical microtubule-targeting agents. Using docetaxel and vinorelbine, two well-established chemotherapeutic agents, we sought to identify genetic alterations sensitizing human HAP1 cells to these drugs. Despite the fact that both drugs act on microtubules, a set of distinct genes were identified whose disruption affects drug sensitivity...
June 2018: Molecular Oncology
https://www.readbyqxmd.com/read/29670855/current-therapies-for-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer-patients
#19
REVIEW
Alexey A Larionov
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the first line, followed by the addition of lapatinib and by a switch to another cytotoxic agent after progression. Results of CLEOPATRA, EMILIA, and TH3RESA trials have changed this clinical practice...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29660315/metronomic-vinorelbine-is-directly-active-on-non-small-cell-lung-cancer-cells-and-sensitizes-the-egfr-l858r-t790m-cells-to-reversible-egfr-tyrosine-kinase-inhibitors
#20
Paola Orlandi, Teresa Di Desidero, Giada Salvia, Beatrice Muscatello, Giulio Francia, Guido Bocci
Metronomic vinorelbine (mVNR) has been described primarily as an antiangiogenic therapy, and no direct effects of mVNR on Non Small Cell Lung Cancer (NSCLC) cells has yet been demonstrated. The aims of this study were i) to establish the direct activity of mVNR on NSCLC cells either EGFR wt or EGFRL858R/T790M , and ii) to quantify the synergism of the combination with reversible EGFR tyrosine kinase inhibitors (TKIs), investigating the underlying mechanism of action. Proliferation assays were performed on A-549 (wt EGFRhigh ), H-292 (EGFR-wt), H-358 (EGFR-wt), H-1975 (EGFRL858R/T790M ) NSCLC cell lines exposed to mVNR, its active metabolite deacetyl-VNR (D-VNR), gefitinib and erlotinib for 144 h treatments...
June 2018: Biochemical Pharmacology
keyword
keyword
31933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"